Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aileen Duffton

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Physics and Imaging in Radiation Oncology|November 17, 2022
Predicting radiotherapy-induced xerostomia in head and neck cancer patients using day-to-day kinetics of radiomics featuresThomas Berger, David J Noble, Leila E A Shelley, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2023
Sub-regional analysis of the parotid glands: model development for predicting late xerostomia with radiomics features in head and neck cancer patientsThomas Berger, David J Noble, Zhuolin Yang, et al.
Physics and Imaging in Radiation Oncology|January 20, 2023
Assessing the generalisability of radiomics features previously identified as predictive of radiation-induced sticky saliva and xerostomiaThomas Berger, David J Noble, Zhuolin Yang, et al.
Disease Models & Mechanisms|April 17, 2025
A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinomaStephanie May, Katrina Stevenson, Bashaer Alqarafi, et al.
Technical Innovations & Patient Support in Radiation Oncology|August 18, 2025
Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical careElena Moreno-Olmedo, Kasia Owczarczyk, Eliot Chadwick, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
BMJ Open|February 2, 2026
Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare dataWilliam H Nailon, David J Noble, Ewen Harrison, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Physics and Imaging in Radiation Oncology|November 17, 2022
Predicting radiotherapy-induced xerostomia in head and neck cancer patients using day-to-day kinetics of radiomics featuresThomas Berger, David J Noble, Leila E A Shelley, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2023
Sub-regional analysis of the parotid glands: model development for predicting late xerostomia with radiomics features in head and neck cancer patientsThomas Berger, David J Noble, Zhuolin Yang, et al.
Physics and Imaging in Radiation Oncology|January 20, 2023
Assessing the generalisability of radiomics features previously identified as predictive of radiation-induced sticky saliva and xerostomiaThomas Berger, David J Noble, Zhuolin Yang, et al.
Disease Models & Mechanisms|April 17, 2025
A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinomaStephanie May, Katrina Stevenson, Bashaer Alqarafi, et al.
Technical Innovations & Patient Support in Radiation Oncology|August 18, 2025
Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical careElena Moreno-Olmedo, Kasia Owczarczyk, Eliot Chadwick, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
BMJ Open|February 2, 2026
Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare dataWilliam H Nailon, David J Noble, Ewen Harrison, et al.
Pageof 3